Patents by Inventor Mark Wall
Mark Wall has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 7414050Abstract: The invention is directed to compounds of Formula I: wherein Z, X, J, R2 and W are set forth in the specification, as well as solvates, hydrates, tautomers and pharmaceutically acceptable salts thereof, that inhibit protein tyrosine kinases, especially c-fms kinase. Methods of treating autoimmune diseases; and diseases with an inflammatory component; treating metastasis from ovarian cancer, uterine cancer, breast cancer, prostate cancer, lung cancer, colon cancer, stomach cancer, hairy cell leukemia; and treating pain, including skeletal pain caused by tumor metastasis or osteoarthritis, or visceral, inflammatory, and neurogenic pain; as well as osteoporosis, Paget's disease, and other diseases in which bone resorption mediates morbidity including rheumatoid arthritis, and other forms of inflammatory arthritis, osteoarthritis, prosthesis failure, osteolytic sarcoma, myeloma, and tumor metastasis to bone with the compounds of Formula I, are also provided.Type: GrantFiled: April 18, 2007Date of Patent: August 19, 2008Assignee: Janssen Pharmaceutica, N.V.Inventors: Carl R. Illig, Shelly K. Ballentine, Jinsheng Chen, Renee Louise DesJarlais, Sanath K. Meegalla, Mark Wall, Kenneth Wilson
-
Publication number: 20080051402Abstract: A method of reducing or inhibiting kinase activity of C-KIT in a cell or a subject, and the use of such compounds for preventing or treating in a subject a cell proliferative disorder and/or disorders related to C-KIT using a compound of the present invention: or a solvate, hydrate, tautomer or pharmaceutically acceptable salt thereof. The present invention is further directed to methods for treating conditions such as cancers and other cell proliferative disorders.Type: ApplicationFiled: April 19, 2007Publication date: February 28, 2008Inventors: Carl Illig, Shelley Ballentine, Jinsheng Chen, Sanath Meegalla, M. Rudolph, Mark Wall, Kenneth Wilson, Renee Desjarlais, Carl Manthey, Christopher Molloy
-
Publication number: 20070249649Abstract: The invention is directed to compounds of Formula I: wherein Z, X, J, R2 and W are set forth in the specification, as well as solvates, hydrates, tautomers and pharmaceutically acceptable salts thereof, that inhibit protein tyrosine kinases, especially c-fms kinase. Methods of treating autoimmune diseases; and diseases with an inflammatory component; treating metastasis from ovarian cancer, uterine cancer, breast cancer, colon cancer, stomach cancer, hairy cell leukemia and non-small lung carcinoma; and treating pain, including skeletal pain caused by tumor metastasis or osteoarthritis, or visceral, inflammatory, and neurogenic pain; as well as osteoporosis, Paget's disease, and other diseases in which bone resorption mediates morbidity including arthritis, prosthesis failure, osteolytic sarcoma, myeloma, and tumor metastasis to bone with the compounds of Formula I, are also provided.Type: ApplicationFiled: April 18, 2007Publication date: October 25, 2007Inventors: Carl R. Illig, Shelley K. Ballentine, Jinsheng Chen, Renee Louise DesJarlais, Sanath K. Meegalla, Mark Wall, Kenneth Wilson
-
Publication number: 20070249593Abstract: The invention is directed to compounds of Formula I: wherein Z, X, J, R2 and W are set forth in the specification, as well as solvates, hydrates, tautomers and pharmaceutically acceptable salts thereof, that inhibit protein tyrosine kinases, especially c-fms kinase. Methods of treating autoimmune diseases; and diseases with an inflammatory component; treating metastasis from ovarian cancer, uterine cancer, breast cancer, prostate cancer, lung cancer, colon cancer, stomach cancer, hairy cell leukemia; and treating pain, including skeletal pain caused by tumor metastasis or osteoarthritis, or visceral, inflammatory, and neurogenic pain; as well as osteoporosis, Paget's disease, and other diseases in which bone resorption mediates morbidity including rheumatoid arthritis, and other forms of inflammatory arthritis, osteoarthritis, prosthesis failure, osteolytic sarcoma, myeloma, and tumor metastasis to bone with the compounds of Formula I, are also provided.Type: ApplicationFiled: April 18, 2007Publication date: October 25, 2007Inventors: Carl R. Illig, Shelley K. Ballentine, Jinsheng Chen, Renee Louise DesJarlais, Sanath K. Meegalla, Mark Wall, Kenneth Wilson
-
Publication number: 20070249680Abstract: The invention is directed to compounds of Formula I: wherein Z, X, J, R2 and W are set forth in the specification, as well as solvates, hydrates, tautomers and pharmaceutically acceptable salts thereof, that inhibit protein tyrosine kinases, especially c-fms kinase. Methods of treating autoimmune diseases; and diseases with an inflammatory component; treating metastasis from ovarian cancer, uterine cancer, breast cancer, prostate cancer, lung cancer, colon cancer, stomach cancer, hairy cell leukemia; and treating pain, including skeletal pain caused by tumor metastasis or osteoarthritis, or visceral, inflammatory, and neurogenic pain; as well as osteoporosis, Paget's disease, and other diseases in which bone resorption mediates morbidity including rheumatoid arthritis, and other forms of inflammatory arthritis, osteoarthritis, prosthesis failure, osteolytic sarcoma, myeloma, and tumor metastasis to bone with the compounds of Formula I, are also provided.Type: ApplicationFiled: April 18, 2007Publication date: October 25, 2007Inventors: Carl R. Illig, Shelley K. Ballentine, Jinsheng Chen, Renee Louise DesJarlais, Sanath K. Meegalla, Bruce E. Tomczuk, Mark Wall, Kenneth Wilson
-
Publication number: 20070249608Abstract: The invention is directed to compounds of Formula I: wherein Z, X, J, R2 and W are set forth in the specification, as well as solvates, hydrates, tautomers and pharmaceutically acceptable salts thereof, that inhibit protein tyrosine kinases, especially c-fms kinase. Methods of treating autoimmune diseases; and diseases with an inflammatory component; treating metastasis from ovarian cancer, uterine cancer, breast cancer, prostate cancer, lung cancer, colon cancer, stomach cancer, hairy cell leukemia; and treating pain, including skeletal pain caused by tumor metastasis or osteoarthritis, or visceral, inflammatory, and neurogenic pain; as well as osteoporosis, Paget's disease, and other diseases in which bone resorption mediates morbidity including rheumatoid arthritis, and other forms of inflammatory arthritis, osteoarthritis, prosthesis failure, osteolytic sarcoma, myeloma, and tumor metastasis to bone with the compounds of Formula I, are also provided.Type: ApplicationFiled: April 18, 2007Publication date: October 25, 2007Inventors: Carl R. Illig, Shelley K. Ballentine, Jinsheng Chen, Renee Louise DesJarlais, Sanath K. Meegalla, Mark Wall, Kenneth Wilson
-
Publication number: 20070149572Abstract: A method of reducing or inhibiting kinase activity of FLT3 in a cell or a subject, and the use of such compounds for preventing or treating in a subject a cell proliferative disorder and/or disorders related to FLT3 using a ompound of the present invention: or a solvate, hydrate, tautomer or pharmaceutically acceptable salt thereof. The present invention is further directed to methods for treating conditions such as cancers and other cell proliferative disorders.Type: ApplicationFiled: October 17, 2006Publication date: June 28, 2007Inventors: Shelley Ballentine, Christian Baumann, Jinsheng Chen, Carl Illig, Sanath Meegalla, M. Rudolph, Robert Tuman, Mark Wall, Kenneth Wilson, Dana Johnson
-
Patent number: 7138530Abstract: Disclosed is a method for treating the symptoms of an acute or chronic disorder mediated by the classical pathway of the complement cascade, comprising administering to a mammal in need of such treatment a therapeutically effective amount of a compound of Formula (I) or a solvate, hydrate or pharmaceutically acceptable salt thereof; wherein R1, R2, R3, R4 and R7 are defined in the specification, Z is SO or SO2, and Ar is an aromatic or heteroaromatic group as defined herein.Type: GrantFiled: May 28, 2003Date of Patent: November 21, 2006Assignee: 3-Dimensional Pharmaceuticals, Inc.Inventors: Nalin Subasinghe, Ehab Khalil, Kristi A. Leonard, Farah Ali, Heather Hufnagel, Jeremy M. Travins, Shelley K. Ballentine, Kenneth T. Wilson, Maxwell D. Cummings, Wenxi Pan, Joan Gushue, Sanath Meegalla, Mark Wall, Jinsheng Chen, Jonathan M. Rudolph, Hui Huang
-
Patent number: 7109354Abstract: Disclosed is a method for treating the symptoms of an acute or chronic disorder mediated by the classical pathway of the complement cascade, comprising administering to a mammal in need of such treatment a therapeutically effective amount of a compound of Formula I or a solvate, hydrate or pharmaceutically acceptable salt thereof; wherein R1, R2, R3, R4 and R7 are defined in the specification, Z is SO or SO2, and Ar is an aromatic or heteroaromatic group as defined herein.Type: GrantFiled: May 28, 2003Date of Patent: September 19, 2006Assignee: 3-Dimensional Pharmaceuticals, Inc.Inventors: Nalin Subasinghe, Ehab Khalil, Kristi Leonard, Farah Ali, Heather Rae Hufnagel, Jeremy M. Travins, Shelley K. Ballentine, Kenneth T. Wilson, Maxwell D. Cummings, Wenxi Pan, Joan Gushue, Sanath Meegalla, Mark Wall, Jinsheng Chen, M. Jonathan Rudolph, Hui Huang
-
Publication number: 20060189623Abstract: The invention is directed to compounds of Formula I: wherein A, X, R2 and W are set forth in the specification, as well as solvates, hydrates, tautomers and pharmaceutically acceptable salts thereof, that inhibit protein tyrosine kinases, especially c-fms kinase. Methods of treating autoimmune diseases; and diseases with an inflammatory component; treating metastasis from ovarian cancer, uterine cancer, breast cancer, colon cancer, stomach cancer, hairy cell leukemia and non-small lung carcinoma; and treating pain, including skeletal pain caused by tumor metastasis or osteoarthritis, or visceral, inflammatory, and neurogenic pain; as well as osteoporosis, Paget's disease, and other diseases in which bone resorption mediates morbidity including arthritis, prosthesis failure, osteolytic sarcoma, myeloma, and tumor metastasis to bone with the compounds of Formula I, are also provided.Type: ApplicationFiled: April 20, 2006Publication date: August 24, 2006Inventors: Carl Illig, Shelley Ballentine, Jinsheng Chen, Sanath Meegalla, M. Rudolph, Mark Wall, Kenneth Wilson, Renee Desjarlais, Carl Manthey, Christopher Flores, Christopher Molloy
-
Publication number: 20060148812Abstract: The invention is directed to compounds of Formula I: wherein A, X, R2 and W are set forth in the specification, as well as solvates, hydrates, tautomers and pharmaceutically acceptable salts thereof, that inhibit protein tyrosine kinases, especially c-fms kinase. Methods of treating autoimmune diseases; and diseases with an inflammatory component; treating metastasis from ovarian cancer, uterine cancer, breast cancer, colon cancer, stomach cancer, hairy cell leukemia and non-small lung carcinoma; and treating pain, including skeletal pain caused by tumor metastasis or osteoarthritis, or visceral, inflammatory, and neurogenic pain; as well as osteoporosis, Paget's disease, and other diseases in which bone resorption mediates morbidity including arthritis, prosthesis failure, osteolytic sarcoma, myeloma, and tumor metastasis to bone with the compounds of Formula I, are also provided.Type: ApplicationFiled: October 20, 2005Publication date: July 6, 2006Inventors: Carl Illig, Shelley Ballentine, Jinsheng Chen, Sanath Meegalla, M. Rudolf, Mark Wall, Ken Wilson, Renee Desjarlais, Carl Manthey, Christopher Flores, Chris Molloy
-
Publication number: 20060100201Abstract: The invention relates to compounds of Formula I: wherein A, X, R2 and W are set forth in the specification, as well as solvates, hydrates, tautomers and pharmaceutically acceptable salts thereof, that inhibit protein tyrosine kinases, especially c-fms kinase. Methods of treating autoimmune diseases; and diseases with an inflammatory component; treating metastasis from ovarian cancer, uterine cancer, breast cancer, colon cancer, stomach cancer, hairy cell leukemia and non-small lung carcinoma; and treating pain, including skeletal pain caused by tumor metastasis or osteoarthritis, or visceral, inflammatory, and neurogenic pain; as well as osteoporosis, Paget's disease, and other diseases in which bone resorption mediates morbidity including arthritis, prosthesis failure, osteolytic sarcoma, myeloma, and tumor metastasis to bone with the compounds of Formula I, are also provided.Type: ApplicationFiled: October 20, 2005Publication date: May 11, 2006Inventors: Carl Illig, Shelley Ballentine, Jinsheng Chen, Sanath Meegalla, M. Jonathan Rudolph, Mark Wall, Kenneth Wilson, Renee DesJarlais, Carl Manthey, Christopher Flores, Christopher Molloy
-
Publication number: 20050234081Abstract: Disclosed is a method for treating the symptoms of an acute or chronic disorder mediated by the classical pathway of the complement cascade, comprising administering to a mammal in need of such treatment a therapeutically effective amount of a compound of Formula (I) or a solvate, hydrate or pharmaceutically acceptable salt thereof; wherein R1, R2, R3, R4 and R7 are defined in the specification, Z is SO or SO2, and Ar is an aromatic or heteroaromatic group as defined herein.Type: ApplicationFiled: May 28, 2003Publication date: October 20, 2005Inventors: Nalin Subasinghe, Ehab Khalil, Kristi Leonard, Farah Ali, Heather Hufnagel, Jeremy Travins, Shelley Ballentine, Kenneth Wilson, Maxwell Cummings, Wenxi Pan, Joan Gushue, Sanath Meegalla, Mark Wall, Jinsheng Chen
-
Publication number: 20050049274Abstract: The invention is directed to compounds of Formulae I and II: wherein R1, R2, R3, R5, R6, Y1, Y2, Y3, Y4 and X are set forth in the specification, as well as solvates, hydrates, tautomers or pharmaceutically acceptable salts thereof, that inhibit protein tyrosine kinases, especially c-fms kinase.Type: ApplicationFiled: July 20, 2004Publication date: March 3, 2005Inventors: Mark Wall, Mark Player, Raymond Patch, Sanath Meegalla, Jian Liu, Carl Illig, Wing Cheung, Jinsheng Chen, Davoud Asgari
-
Publication number: 20040259833Abstract: This invention provides broad-spectrum antibiotics that are inhibitors of bacterial adenine DNA methyltransferases.Type: ApplicationFiled: June 25, 2004Publication date: December 23, 2004Applicants: The Board of Trustees of the Leland Stanford Junior University, The Penn State Research FoundationInventors: Stephen J. Benkovic, Lucille Shapiro, Stephen J. Baker, Daphne C. Wahnon, Mark Wall
-
Publication number: 20040009995Abstract: Disclosed is a method for treating the symptoms of an acute or chronic disorder mediated by the classical pathway of the complement cascade, comprising administering to a mammal in need of such treatment a therapeutically effective amount of a compound of Formula I 1Type: ApplicationFiled: May 28, 2003Publication date: January 15, 2004Applicant: 3-Dimensional Pharmaceuticals, Inc.Inventors: Nalin Subasinghe, Ehab Khalil, Kristi Leonard, Farah Ali, Heather Rae Hufnagel, Jeremy M. Travins, Shelley K. Ballentine, Kenneth T. Wilson, Maxwell D. Cummings, Wenxi Pan, Joan Gushue, Sanath Meegalla, Mark Wall, Jinsheng Chen, M. Jonathan Rudolph, Hui Huang
-
Patent number: 6228512Abstract: High reflectance, low intrinsic roughness and low stress multilayer systems for extreme ultraviolet (EUV) lithography comprise amorphous layers MoRu and crystalline Be layers. Reflectance greater than 70% has been demonstrated for MoRu/Be multilayers with 50 bilayer pairs. Optical throughput of MoRu/Be multilayers can be 30-40% higher than that of Mo/Be multilayer coatings. The throughput can be improved using a diffusion barrier to make sharper interfaces. A capping layer on the top surface of the multilayer improves the long-term reflectance and EUV radiation stability of the multilayer by forming a very thin native oxide that is water resistant.Type: GrantFiled: May 26, 1999Date of Patent: May 8, 2001Assignee: The Regents of the University of CaliforniaInventors: Sasa C. Bajt, Mark A. Wall
-
Patent number: 6110066Abstract: A hybrid vehicle includes an internal combustion engine, an electric motor/generator and a battery. The drivetrain includes a planetary gear in which the engine is coupled to the sun gear, the motor/generator to the ring gear and the vehicle wheels to the carrier of the planetary. A controller switches the vehicle between electric, assist, charge and regenerative modes of operation and substantially decouples the engine speed from the vehicle speed, enabling the engine to operate at peak efficiency. Additional overdrives are included to enable the engine to operate at optimum speed in the various modes of operation.Type: GrantFiled: February 5, 1998Date of Patent: August 29, 2000Assignee: Southwest Research InstituteInventors: Ashok Nedungadi, Mark Walls, Dimitrios Dardalis